Navigation Links
Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
Date:7/21/2008

LONDON, July 21 /PRNewswire/ -- The University of Oxford Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) proposed that the hypothesis-generating results of the SEAS trial of ezetimibe should be tested by reviewing the combined cancer results from the SHARP and IMPROVE-IT trials of ezetimibe, and reporting on the overall findings to the relevant regulatory authorities, independently of the drug manufacturers.

The two hypothesis-testing trials (SHARP and IMPROVE-IT) contain about four times as many cancers as the SEAS trial. They do not confirm the hypothesis raised by the SEAS trial that treatment increases the overall risk of developing cancer. In addition, there is no increase with time in the relative risk (active vs placebo) suggested by the cancer incidence and mortality from all 3 trials together (or just from the pair of hypothesis-testing trials). Consequently, the SEAS, SHARP and IMPROVE-IT trials do not provide credible evidence of any adverse effect on cancer.

Allocation to 5 years of substantial LDL-cholesterol lowering by a statin has been shown previously to have no apparent effect on cancer. The Cholesterol Treatment Trialists' collaboration has published results (Lancet 2005;366: 1267-78) based on 90,000 patients randomised evenly between statin and control. Based on 5530 patients with cancer onset after randomisation, the statin vs control relative risk was 0.997 (with 95% confidence interval 0.95-1.05; not significant). Of these patients, 2163 died of their cancer during the scheduled follow-up period; the relative risk for cancer death was 1.01 (with 95% confidence interval 0.91-1.12; not significant).

In the final results from the SEAS trial, there appears to be a small increase in total cancer incidence in the group allocated ezetimibe + statin, but this is based on only 102 vs 67 cancer cases (including 39 vs 23 fatal cases) and there is no significant increase in any particular type of cancer. '/>"/>

SOURCE ;
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
3. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
4. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
5. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
6. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
7. Independent Studies Report on Possible Roles for Cylexs Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
8. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Promise of Vicals CMV Vaccine Noted by Independent Experts
11. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  Sorrento Therapeutics, Inc. (OTCBB: SRNE; or ... Small Business Technology Transfer Research (STTR) grant (#1R42AI098182-02) ... Diseases (NIAID), a division of the National Institutes ... human antibody therapeutics to combat Staphylococcus aureus ... including methicillin-resistant S. aureus (MRSA), was ...
(Date:5/17/2013)... CHAMPAIGN, Ill. , May 17, 2013  Sony ... new Sony SP6800 Spectral Analyzer (SP6800).  Sony will be ... 2013, which will be held at the ... San Diego, California , from May 20 - ... Sony,s second analytical system, incorporating commercial audio-visual technologies into ...
(Date:5/17/2013)... 17, 2013 /PRNewswire-iReach/ -- The escalation of new ... placing renewed emphasis on alternate delivery technologies. Alternate ... number of factors are converging to create both ... their delivery device partners . These include new ... growing trend toward self-administration for chronic diseases, shifting ...
Breaking Medicine Technology:Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3
... , July 16 Warner Chilcott ... received a communication from the U.S. Food & Drug Administration ... delayed-release tablets extending the Prescription Drug User Fee Act (PDUFA) ... additional information solicited by the FDA and previously provided by ...
... , July 15 LyoTechnica, LLC has ... drug development services for injectable pharmaceuticals. The company and ... in lyophilization and liquid dosage form development as well ... of parenteral drugs. The company offers analytical and formulation ...
Cached Medicine Technology:Warner Chilcott Announces 3-Month Extension of PDUFA Date on Next Generation Actonel Product 2Warner Chilcott Announces 3-Month Extension of PDUFA Date on Next Generation Actonel Product 3Formation of Contract Parenteral Drug Development Services Company Announced 2
(Date:5/18/2013)... Orlando, FL (May 18, 2013) A ground-breaking ... colorectal care, according to research presented today at ... optimizing the minimal withdrawal time for colonoscopies and ... , During colonoscopy, doctors use a device called ... test for colorectal cancer allows a doctor to ...
(Date:5/18/2013)... New York (PRWEB) May 18, 2013 ... pelvic mesh products continue to move forward in a ... Court, Bernstein Liebhard LLP reports. According to a notice ... in the Ethicon pelvic mesh litigation will be held ... 2,755 complaints have been filed in the proceeding on ...
(Date:5/18/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay News) -- ... drink, but new research shows that college women are more ... basis than are college men. Much of this ... safe on a weekly basis is much lower for women ... 14 for men. But, there,s good reason for that difference. ...
(Date:5/18/2013)... After working diligently for months and putting in ... the integration of the fitment specs for the redesigned 2012 ... stun the automobile market with its extraordinary features and unique ... as the latest entry in the size it up ... the year 2013. , Aptly suiting its name, 2012 ...
(Date:5/18/2013)... 2013 Family Magazine of Washington DC was ... Follow Media Consulting, Inc. in the category of Summer ... and dedication of the areas best in the ultimate guide ... parenting better than Brenda Hyde, a mother of four and ... know about the vast resources available to them in the ...
Breaking Medicine News(10 mins):Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3Health News:College Women More Prone to Problem Drinking Than Men: Study 2Health News:College Women More Prone to Problem Drinking Than Men: Study 3Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:Summer Camps in DC "Best of the Best" Awarded to Family Magazine of Washington DC for Excellence by Follow Media Consulting, Inc. 2
... suitable treatment mode for women diagnosed with breast cancer who ... should consider hormonal treatments to reduce their risk of a ... study led by researchers at the University of Michigan Comprehensive ... genetic mutation who had their ovaries removed or took the ...
... as a custom rather than as a matter of choice. ... waywardness //in the females while some clans even consider it ... initiating teenage girls into adulthood. ,As tradition goes ... which are often unsterilized. In addition the area of excision ...
... in regulating cell death, a Queen’s University study has found. ... be used to promote cell death in cancer cells but ... in neuronal cells in the case of Alzheimer’s or Parkinson’s. ... Medicine with the Cancer Biology and Genetics division of Queen’s ...
... new survey nearly 12 million Americans are affected by peripheral ... arteries are blocked that brings blood to the legs due ... is likely to increase in the coming decades and it’s ... drugs to treat it. , ,By examining the physiology ...
... sector educational group Amity Institutions have decided to launch ... plans to set up academic and training infrastructure in ... in an effort to expand the educational facilities in ... President, and board member of Ritnand Balved Education Foundation, ...
... the breast cancer in younger black women nothing significant has ... women the number of black women affected by breast cancer ... the black women is much higher when compared with the ... 50 have a 77 percent of mortality rate. ...
Cached Medicine News:Health News:Breast-Sparing Surgery: An Optional Treatment Mode For Women With Breast Cancer 2Health News:Breast-Sparing Surgery: An Optional Treatment Mode For Women With Breast Cancer 3Health News:Female Circumcision Rampant in Africa 2Health News:Protein’s role in regulating cell death sets direction for Alzheimer’s, Parkinson’s and cancer resea 2Health News:New Test to Diagnose the Peripheral Arterial Disease (PAD) 2Health News:Breast Cancer Mortality Rate is Higher Among Black Women 2Health News:Breast Cancer Mortality Rate is Higher Among Black Women 3
The Onar®Lp test system is an in vitro test for the qualitative diagnosis of legionella in clinical samples....
The Onar®Lp -QP test system is an in vitro test for the quantitative diagnosis of legionella in clinical samples....
Designed for OSA patients who have difficulty with conventional CPAP therapy, the ResMed SULLIVAN Comfort system is a solution for those who need an alternative to CPAP....
... an approach to treatment that ... pressure range to 25 cm ... treat patients with severe OSA. ... integrated humidification and built-in Encore® ...
Medicine Products: